Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2017 1
2020 2
2021 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients.
Willeit P, Tschiderer L, Allara E, Reuber K, Seekircher L, Gao L, Liao X, Lonn E, Gerstein HC, Yusuf S, Brouwers FP, Asselbergs FW, van Gilst W, Anderssen SA, Grobbee DE, Kastelein JJP, Visseren FLJ, Ntaios G, Hatzitolios AI, Savopoulos C, Nieuwkerk PT, Stroes E, Walters M, Higgins P, Dawson J, Gresele P, Guglielmini G, Migliacci R, Ezhov M, Safarova M, Balakhonova T, Sato E, Amaha M, Nakamura T, Kapellas K, Jamieson LM, Skilton M, Blumenthal JA, Hinderliter A, Sherwood A, Smith PJ, van Agtmael MA, Reiss P, van Vonderen MGA, Kiechl S, Klingenschmid G, Sitzer M, Stehouwer CDA, Uthoff H, Zou ZY, Cunha AR, Neves MF, Witham MD, Park HW, Lee MS, Bae JH, Bernal E, Wachtell K, Kjeldsen SE, Olsen MH, Preiss D, Sattar N, Beishuizen E, Huisman MV, Espeland MA, Schmidt C, Agewall S, Ok E, Aşçi G, de Groot E, Grooteman MPC, Blankestijn PJ, Bots ML, Sweeting MJ, Thompson SG, Lorenz MW; PROG-IMT and the Proof-ATHERO Study Groups. Willeit P, et al. Circulation. 2020 Aug 18;142(7):621-642. doi: 10.1161/CIRCULATIONAHA.120.046361. Epub 2020 Jun 17. Circulation. 2020. PMID: 32546049 Free PMC article.
Protein Biomarkers of New-Onset Heart Failure: Insights From the Heart Omics and Ageing Cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart Study.
Girerd N, Levy D, Duarte K, Ferreira JP, Ballantyne C, Collier T, Pizard A, Björkman J, Butler J, Clark A, Cleland JG, Delles C, Diez J, González A, Hazebroek M, Ho J, Huby AC, Hwang SJ, Latini R, Mariottoni B, Mebazaa A, Pellicori P, Sattar N, Sever P, Staessen JA, Verdonschot J, Heymans S, Rossignol P, Zannad F. Girerd N, et al. Circ Heart Fail. 2023 May;16(5):e009694. doi: 10.1161/CIRCHEARTFAILURE.122.009694. Epub 2023 May 16. Circ Heart Fail. 2023. PMID: 37192292 Free PMC article.
Proteins associated with incident HF in all cohorts were BNP (brain natriuretic peptide), NT-proBNP (N-terminal pro-B-type natriuretic peptide), eukaryotic translation initiation factor 4E-BP1 (4E-binding protein 1), hepatocyte growth factor (HGF), Gal-9 (galectin-9), TGF- …
Proteins associated with incident HF in all cohorts were BNP (brain natriuretic peptide), NT-proBNP (N-terminal pro-B-type natriureti …
Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial.
Ravassa S, López B, Ferreira JP, Girerd N, Bozec E, Pellicori P, Mariottoni B, Cosmi F, Hazebroek M, Verdonschot JAJ, Cuthbert J, Petutschnigg J, Moreno MU, Heymans S, Staessen JA, Pieske B, Edelmann F, Clark AL, Cleland JGF, Zannad F, Díez J, González A; HOMAGE Trial Committees and Investigators. Ravassa S, et al. Eur J Heart Fail. 2022 Feb;24(2):321-331. doi: 10.1002/ejhf.2394. Epub 2021 Dec 9. Eur J Heart Fail. 2022. PMID: 34841615 Free article. Clinical Trial.
METHODS AND RESULTS: Patients at risk of HF were randomized to spironolactone (n = 260) or not (n = 255). Blood sampling and echocardiography were done at baseline, one and nine months. ...Spironolactone reduced LAVI after one and nine months only for those patients …
METHODS AND RESULTS: Patients at risk of HF were randomized to spironolactone (n = 260) or not (n = 255). Blood sampling and e …
The 67P/Churyumov-Gerasimenko observation campaign in support of the Rosetta mission.
Snodgrass C, A'Hearn MF, Aceituno F, Afanasiev V, Bagnulo S, Bauer J, Bergond G, Besse S, Biver N, Bodewits D, Boehnhardt H, Bonev BP, Borisov G, Carry B, Casanova V, Cochran A, Conn BC, Davidsson B, Davies JK, de León J, de Mooij E, de Val-Borro M, Delacruz M, DiSanti MA, Drew JE, Duffard R, Edberg NJT, Faggi S, Feaga L, Fitzsimmons A, Fujiwara H, Gibb EL, Gillon M, Green SF, Guijarro A, Guilbert-Lepoutre A, Gutiérrez PJ, Hadamcik E, Hainaut O, Haque S, Hedrosa R, Hines D, Hopp U, Hoyo F, Hutsemékers D, Hyland M, Ivanova O, Jehin E, Jones GH, Keane JV, Kelley MSP, Kiselev N, Kleyna J, Kluge M, Knight MM, Kokotanekova R, Koschny D, Kramer EA, López-Moreno JJ, Lacerda P, Lara LM, Lasue J, Lehto HJ, Levasseur-Regourd AC, Licandro J, Lin ZY, Lister T, Lowry SC, Mainzer A, Manfroid J, Marchant J, McKay AJ, McNeill A, Meech KJ, Micheli M, Mohammed I, Monguió M, Moreno F, Muñoz O, Mumma MJ, Nikolov P, Opitom C, Ortiz JL, Paganini L, Pajuelo M, Pozuelos FJ, Protopapa S, Pursimo T, Rajkumar B, Ramanjooloo Y, Ramos E, Ries C, Riffeser A, Rosenbush V, Rousselot P, Ryan EL, Santos-Sanz P, Schleicher DG, Schmidt M, Schulz R, Sen AK, Somero A, Sota A, Stinson A, Sunshine JM, Thompson A, Tozzi … See abstract for full author list ➔ Snodgrass C, et al. Philos Trans A Math Phys Eng Sci. 2017 Jul 13;375(2097):20160249. doi: 10.1098/rsta.2016.0249. Philos Trans A Math Phys Eng Sci. 2017. PMID: 28554971 Free PMC article.
Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial.
Pellicori P, Ferreira JP, Mariottoni B, Brunner-La Rocca HP, Ahmed FZ, Verdonschot J, Collier T, Cuthbert JJ, Petutschnigg J, Mujaj B, Girerd N, González A, Clark AL, Cosmi F, Staessen JA, Heymans S, Latini R, Rossignol P, Zannad F, Cleland JGF. Pellicori P, et al. Eur J Heart Fail. 2020 Sep;22(9):1711-1723. doi: 10.1002/ejhf.1716. Epub 2020 Jan 16. Eur J Heart Fail. 2020. PMID: 31950604 Free article. Clinical Trial.
The primary endpoint was the interaction between change in serum concentrations of procollagen type III N-terminal propeptide (PIIINP) and treatment with spironolactone according to median plasma concentrations of galectin-3 at baseline. ...At baseline, medians (interquart …
The primary endpoint was the interaction between change in serum concentrations of procollagen type III N-terminal propeptide (PIIINP …
Polymer Light-Emitting Electrochemical Cells: In Situ Formation of a Light-Emitting p-n Junction.
Pei Q, Yang Y, Yu G, Zhang C, Heeger AJ. Pei Q, et al. J Am Chem Soc. 1996 Apr 24;118(16):3922-9. doi: 10.1021/ja953695q. J Am Chem Soc. 1996. PMID: 27579778
When externally biased, the conjugated polymers are p-doped and n-doped on opposite sides of the polymer layer, and a light-emitting p-n junction is formed in between. ...The devices reached 8 cd/m(2) at 3 V and 100 cd/m(2) at 4 V, with an external qua …
When externally biased, the conjugated polymers are p-doped and n-doped on opposite sides of the polymer layer, and a light-emitting …